- Home
- Publications
- Publication Search
- Publication Details
Title
Cholesterol-Lowering Agents
Authors
Keywords
-
Journal
CIRCULATION RESEARCH
Volume 124, Issue 3, Pages 364-385
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2019-02-01
DOI
10.1161/circresaha.118.313238
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial
- (2019) Michelle L. O'Donoghue et al. CIRCULATION
- Willingness to be Re-initiated on a Statin (From the REasons for Geographic And Racial Differences in Stroke [REGARDS] Study)
- (2018) Matthew T. Mefford et al. AMERICAN JOURNAL OF CARDIOLOGY
- Lp(a) and Cardiovascular Outcomes: an Analysis from the ODYSSEY OUTCOMES Trial
- (2018) Vera Bittner et al. ATHEROSCLEROSIS SUPPLEMENTS
- Attainment of Recommended Lipid Targets in Patients With Familial Hypercholesterolemia: Real-World Experience With PCSK9 Inhibitors
- (2018) Omar Razek et al. CANADIAN JOURNAL OF CARDIOLOGY
- Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: An Analysis from FOURIER
- (2018) Marc S. Sabatine et al. CIRCULATION
- Inflammatory and Cholesterol Risk in the FOURIER Trial
- (2018) Erin A. Bohula et al. CIRCULATION
- Low-Grade Inflammation Modifies Cardiovascular Risk Even at Very Low LDL-C Levels
- (2018) Wolfgang Koenig CIRCULATION
- Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy
- (2018) Aruna D. Pradhan et al. CIRCULATION
- PCSK9: A potential regulator of apoE/apoER2 against inflammation in atherosclerosis?
- (2018) Xue-qin Bai et al. CLINICA CHIMICA ACTA
- The ever-expanding saga of the proprotein convertases and their roles in body homeostasis
- (2018) Nabil G. Seidah et al. CURRENT OPINION IN LIPIDOLOGY
- Population specific genetic heterogeneity of familial hypercholesterolemia in South Africa
- (2018) Natalie Smyth et al. CURRENT OPINION IN LIPIDOLOGY
- Familial hypercholesterolemia
- (2018) Martine Paquette et al. CURRENT OPINION IN LIPIDOLOGY
- The role of patient registries for rare genetic lipid disorders
- (2018) David M. Ng et al. CURRENT OPINION IN LIPIDOLOGY
- Efficacy and Safety of Evolocumab in Patients with Type 2 Diabetes Mellitus and Hypercholesterolemia or Mixed Dyslipidemia
- (2018) ROBERT S. ROSENSON et al. DIABETES
- Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis
- (2018) Ye-Xuan Cao et al. DIABETES OBESITY & METABOLISM
- Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics
- (2018) Gerald F Watts et al. EUROPEAN HEART JOURNAL
- Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting
- (2018) Rutger Verbeek et al. EUROPEAN HEART JOURNAL
- PCSK9 inhibition and Lp(a) reduction: another piece of the puzzle?
- (2018) Angela Pirillo et al. EUROPEAN HEART JOURNAL
- Loss-of-function PCSK9 mutants evade the unfolded protein response sensor GRP78 and fail to induce endoplasmic reticulum stress when retained
- (2018) Paul Lebeau et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia
- (2018) Merel L. Hartgers et al. Journal of Clinical Lipidology
- Alirocumab in high-risk patients: Observations from the open-label expanded use program
- (2018) Charles J. Glueck et al. Journal of Clinical Lipidology
- Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab
- (2018) Paul M Ridker et al. Journal of Clinical Lipidology
- R46L polymorphism in the PCSK9 gene: Relationship to lipid levels, subclinical vascular disease, and erectile dysfunction
- (2018) Jose M. Mostaza et al. Journal of Clinical Lipidology
- Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy
- (2018) Merel L. Hartgers et al. Journal of Clinical Lipidology
- Low-density lipoprotein cholesterol response after statin initiation among persons living with human immunodeficiency virus
- (2018) Greer A. Burkholder et al. Journal of Clinical Lipidology
- The role of lipoprotein (a) in chronic kidney disease
- (2018) Jemma C. Hopewell et al. JOURNAL OF LIPID RESEARCH
- The Evolving Future of PCSK9 Inhibitors
- (2018) Robert S. Rosenson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The complex molecular genetics of familial hypercholesterolaemia
- (2018) Amanda J. Berberich et al. Nature Reviews Cardiology
- Genome-wide analysis yields new loci associating with aortic valve stenosis
- (2018) Anna Helgadottir et al. Nature Communications
- Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries
- (2018) Seyedeh M. Zekavat et al. Nature Communications
- PCSK9 induces a pro-inflammatory response in macrophages
- (2018) Chiara Ricci et al. Scientific Reports
- Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice
- (2018) José Tuñón et al. European Journal of Preventive Cardiology
- Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm
- (2018) Seamus C. Harrison et al. JAMA Cardiology
- Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies
- (2018) Stephen Burgess et al. JAMA Cardiology
- Whole-Gene Duplication of PCSK9 as a Novel Genetic Mechanism for Severe Familial Hypercholesterolemia
- (2018) Michael A. Iacocca et al. CANADIAN JOURNAL OF CARDIOLOGY
- Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies
- (2018) Leslie Cho et al. CARDIOVASCULAR DRUGS AND THERAPY
- Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials
- (2018) L. A. Leiter et al. DIABETIC MEDICINE
- Medical Expenditures Among Medicare Beneficiaries with Statin-Associated Adverse Effects Following Myocardial Infarction
- (2018) Lisandro D. Colantonio et al. CARDIOVASCULAR DRUGS AND THERAPY
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trends in Utilization of Statin Therapy and Contraindicated Statin Use in HIV‐‐Infected Adults Treated With Antiretroviral Therapy From 2007 Through 2015
- (2018) Robert S. Rosenson et al. Journal of the American Heart Association
- PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia
- (2017) Sophie J. Bernelot Moens et al. EUROPEAN HEART JOURNAL
- Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke
- (2017) Jemma C Hopewell et al. EUROPEAN HEART JOURNAL
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- PCSK9 inhibitor therapy in homozygous familial defective apolipoprotein B-100 due to APOB R3500Q: A case report
- (2017) Lars Andersen et al. Journal of Clinical Lipidology
- Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia
- (2017) John J.P. Kastelein et al. Journal of Clinical Lipidology
- A case of autosomal recessive hypercholesterolemia responsive to proprotein convertase subtilisin/kexin 9 inhibition
- (2017) Eoin Francis Fahy et al. Journal of Clinical Lipidology
- Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia
- (2017) Joep C. Defesche et al. Journal of Clinical Lipidology
- Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia
- (2017) G. Kees Hovingh et al. Journal of Clinical Lipidology
- Can LDL cholesterol be too low? Possible risks of extremely low levels
- (2017) A. G. Olsson et al. JOURNAL OF INTERNAL MEDICINE
- Use of next-generation sequencing to detectLDLRgene copy number variation in familial hypercholesterolemia
- (2017) Michael A. Iacocca et al. JOURNAL OF LIPID RESEARCH
- A Test in Context: Lipoprotein(a)
- (2017) Sotirios Tsimikas JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Optimizing Cholesterol Treatment in Patients With Muscle Complaints
- (2017) Robert S. Rosenson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab
- (2017) Jennifer G. Robinson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- HIV and Ischemic Heart Disease
- (2017) Ahmed Vachiat et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
- (2017) Robert P Giugliano et al. LANCET
- Cognitive Function in a Randomized Trial of Evolocumab
- (2017) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Leveraging human genetics to guide drug target discovery
- (2017) Nathan O. Stitziel et al. TRENDS IN CARDIOVASCULAR MEDICINE
- Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis
- (2017) Leo E Akioyamen et al. BMJ Open
- Low LDL cholesterol,PCSK9andHMGCRgenetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study
- (2017) Marianne Benn et al. BMJ-British Medical Journal
- Low LDL cholesterol,PCSK9andHMGCRgenetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study
- (2017) Marianne Benn et al. BMJ-British Medical Journal
- PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and StrokeCLINICAL PERSPECTIVE
- (2017) Shia T. Kent et al. Circulation-Cardiovascular Genetics
- Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study
- (2017) Frederick J Raal et al. Lancet Diabetes & Endocrinology
- PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
- (2017) Amand F Schmidt et al. Lancet Diabetes & Endocrinology
- Familial hypercholesterolaemia
- (2017) Joep C. Defesche et al. Nature Reviews Disease Primers
- Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease
- (2017) Gregg C. Fonarow et al. JAMA Cardiology
- Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV
- (2017) Markella V Zanni et al. Open Forum Infectious Diseases
- Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor)
- (2017) Aurélie Thedrez et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
- (2017) Marc P. Bonaca et al. CIRCULATION
- PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment
- (2017) Matthew T. Mefford et al. CIRCULATION
- Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials
- (2016) Paul M. Ridker et al. AMERICAN HEART JOURNAL
- Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV)
- (2016) Rishi Puri et al. AMERICAN HEART JOURNAL
- Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial
- (2016) Marc S. Sabatine et al. AMERICAN HEART JOURNAL
- Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis
- (2016) Xiaole Su et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained ClinicallyHighlights
- (2016) Jian Wang et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
- (2016) Alberico L. Catapano et al. ATHEROSCLEROSIS
- PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study
- (2016) Jin M. Cheng et al. ATHEROSCLEROSIS
- Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease
- (2016) Evan A. Stein et al. CARDIOVASCULAR DRUGS AND THERAPY
- Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms
- (2016) Hagai Tavori et al. CARDIOVASCULAR RESEARCH
- Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy HumansClinical Perspective
- (2016) Gissette Reyes-Soffer et al. CIRCULATION
- Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin/kexin type 9
- (2016) Bryce Chackerian et al. CURRENT OPINION IN LIPIDOLOGY
- Recent explanatory trials of the mode of action of drug therapies on lipoprotein metabolism
- (2016) Dick C. Chan et al. CURRENT OPINION IN LIPIDOLOGY
- New developments in proprotein convertase subtilisin–kexin 9ʼs biology and clinical implications
- (2016) Nabil G. Seidah CURRENT OPINION IN LIPIDOLOGY
- Coding-sequence variants are associated with blood lipid levels in 14,473 Chinese
- (2016) Xiangfeng Lu et al. HUMAN MOLECULAR GENETICS
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients
- (2016) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
- (2016) Dhruv S. Kazi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association Between Low-Density Lipoprotein Cholesterol–Lowering Genetic Variants and Risk of Type 2 Diabetes
- (2016) Luca A. Lotta et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance
- (2016) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Proprotein convertase subtilisin/Kexin type 9 (PCSK9) single domain antibodies are potent inhibitors of low density lipoprotein receptor degradation.
- (2016) Elodie Weider et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation
- (2016) Delia Susan-Resiga et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role
- (2016) Frederick J. Raal et al. JOURNAL OF LIPID RESEARCH
- Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology
- (2016) Børge G. Nordestgaard et al. JOURNAL OF LIPID RESEARCH
- 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
- (2016) Donald M. Lloyd-Jones et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
- (2016) Brian A. Ference et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy
- (2016) Q Feng et al. PHARMACOGENOMICS JOURNAL
- Oxidized Low‐Density Lipoprotein (OxLDL)–Treated Dendritic Cells Promote Activation of T Cells in Human Atherosclerotic Plaque and Blood, Which Is Repressed by Statins: microRNA let‐7c Is Integral to the Effect
- (2016) Johan Frostegård et al. Journal of the American Heart Association
- Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel
- (2016) Raul D Santos et al. Lancet Diabetes & Endocrinology
- Hemodynamic Shear Stress via ROS Modulates PCSK9 Expression in Human Vascular Endothelial and Smooth Muscle Cells and Along the Mouse Aorta
- (2015) Zufeng Ding et al. ANTIOXIDANTS & REDOX SIGNALING
- Effects of Evolocumab on Vitamin E and Steroid Hormone LevelsNovelty and Significance
- (2015) Dirk J. Blom et al. CIRCULATION RESEARCH
- Characterization of Autosomal Dominant Hypercholesterolemia Caused byPCSK9Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal AntibodyCLINICAL PERSPECTIVE
- (2015) Paul N. Hopkins et al. Circulation-Cardiovascular Genetics
- Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor
- (2015) Rocco Romagnuolo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Local effects of human PCSK9 on the atherosclerotic lesion
- (2015) Ilaria Giunzioni et al. JOURNAL OF PATHOLOGY
- Characterization of the First PCSK9 Gain of Function Homozygote
- (2015) Ana Catarina Alves et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization of Autosomal Dominant Hypercholesterolemia Caused byPCSK9Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal AntibodyCLINICAL PERSPECTIVE
- (2015) Paul N. Hopkins et al. Circulation-Cardiovascular Genetics
- Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
- (2014) Gregory G. Schwartz et al. AMERICAN HEART JOURNAL
- Apolipoprotein E receptor-2 deficiency enhances macrophage susceptibility to lipid accumulation and cell death to augment atherosclerotic plaque progression and necrosis
- (2014) Meaghan D. Waltmann et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
- (2014) M. Cuchel et al. EUROPEAN HEART JOURNAL
- Clusterin Is a Ligand for Apolipoprotein E Receptor 2 (ApoER2) and Very Low Density Lipoprotein Receptor (VLDLR) and Signals via the Reelin-signaling Pathway
- (2014) Christian Leeb et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Lipoprotein(a) mass: A massively misunderstood metric
- (2014) Joseph P. McConnell et al. Journal of Clinical Lipidology
- Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial
- (2014) Patrick M. Moriarty et al. Journal of Clinical Lipidology
- Normalization of Low-Density Lipoprotein Receptor Expression in Receptor Defective Homozygous Familial Hypercholesterolemia by Inhibition of PCSK9 With Alirocumab
- (2014) Gilles Lambert et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures
- (2014) Jeffrey L. Anderson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 is a critical regulator of the innate immune response and septic shock outcome
- (2014) K. R. Walley et al. Science Translational Medicine
- Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia
- (2013) Evan A. Stein et al. CIRCULATION
- Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
- (2013) B. G. Nordestgaard et al. EUROPEAN HEART JOURNAL
- High-sensitivity C-reactive protein and atherosclerotic disease: From improved risk prediction to risk-guided therapy
- (2013) Wolfgang Koenig INTERNATIONAL JOURNAL OF CARDIOLOGY
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)
- (2013) Maryssa Canuel et al. PLoS One
- Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice
- (2012) Maxime Denis et al. CIRCULATION
- Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia
- (2012) Frederick Raal et al. CIRCULATION
- Lipoprotein(a)
- (2012) Joseph B. Dubé et al. CURRENT OPINION IN LIPIDOLOGY
- Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI
- (2011) Bas J.M. Peters et al. ATHEROSCLEROSIS
- Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
- (2011) Nicola Ferri et al. ATHEROSCLEROSIS
- Low-Density Lipoprotein Receptor–Related Protein 1 Prevents Early Atherosclerosis by Limiting Lesional Apoptosis and Inflammatory Ly-6C high Monocytosis
- (2011) Patricia G. Yancey et al. CIRCULATION
- Statins and the risk of new-onset diabetes
- (2011) David Preiss et al. CURRENT OPINION IN LIPIDOLOGY
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
- (2011) Colin Baigent et al. LANCET
- PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax–caspase9–caspase3 pathway
- (2011) Chun-Yan Wu et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Macrophage LRP-1 Controls Plaque Cellularity by Regulating Efferocytosis and Akt Activation
- (2010) Patricia G. Yancey et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Lipoprotein(a) as a cardiovascular risk factor: current status
- (2010) Børge G. Nordestgaard et al. EUROPEAN HEART JOURNAL
- PCSK9R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease
- (2010) Marianne Benn et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Comprehensive Analysis of Genomic Variation in the LPA Locus and Its Relationship to Plasma Lipoprotein(a) in South Asians, Chinese, and European Caucasians
- (2009) Matthew B. Lanktree et al. Circulation-Cardiovascular Genetics
- Mutation S462P in the PCSK9 gene reduces secretion of mutant PCSK9 without affecting the autocatalytic cleavage
- (2008) Jamie Cameron et al. ATHEROSCLEROSIS
- Self-Association of Human PCSK9 Correlates with Its LDLR-Degrading Activity†
- (2008) Daping Fan et al. BIOCHEMISTRY
- PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans
- (2008) Thilina Dewpura et al. FEBS Journal
- Determination of lipoprotein(a) kringle repeat number from genomic DNA: copy number variation genotyping using qPCR
- (2008) Matthew B. Lanktree et al. JOURNAL OF LIPID RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started